![Vontobel Financial Products GmbH](/common/images/company/BIT_F17381.png)
Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its previously announced $2.4 billion acquisition of Medarex, Inc. (NASDAQ: MEDX) (“Medarex”...
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the depositary for its tender offer for all the outstanding common stock of Medarex has advised that, as of the...
NEW DELHI, INDIA -- (Marketwire) -- 08/25/09 -- TheFortuneFinancial.com provides the highest level of independent research and investment strategies with the sole purpose of consistently...
Bristol-Myers Squibb Co. (BMY) said it extended the deadline for its tender offer to buy shares of partner Medarex Inc. (MEDX) amid low shareholder support. As of 9 a.m. EDT Thursday, about 8.7...
Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has extended its previously announced cash tender offer, through its wholly-owned subsidiary, Puma Acquisition...
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired...
LONDON -- (Marketwire) -- 08/11/09 -- Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a...
BALTIMORE, MD -- (Marketwire) -- 08/04/09 -- The law firm of Brower Piven, A Professional Corporation, today announced that securities class actions have been commenced on behalf of current...
Medarex, Inc. (NASDAQ:MEDX) announced today its financial results for the three-month period ended June 30, 2009. Medarex's net loss for the quarter ended June 30, 2009 was...
Bristol-Myers Squibb Co.'s (BMY) $2.1 billion purchase of Medarex Inc. (MEDX), with a premium exceeding 90%, demonstrates that companies developing biologic drugs are still able to command high...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.